Analysis of submicron-sized niflumic acid crystals prepared by electrospray crystallization

Journal of Pharmaceutical and Biomedical Analysis

Volumn 76, Issue , 2013, Pages 1-7

  Ambrus, Rita ^a   Radacsi, Norbert ^b   Szunyogh, Tímea ^a   van der Heijden, Antoine E M ^b,c   ter Horst, Joop H ^b   Szabó Révész, Piroska ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Anti solvent crystallization; Electrospray crystallization; Nanoparticles; Niflumic acid; Physico chemical analysis; Solvent evaporation

Indexed keywords

NIFLUMIC ACID;

ARTICLE; CRYSTAL; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; ELECTROSPRAY CRYSTALLIZATION; INFRARED SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

ACETONE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DRUG COMPOUNDING; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NIFLUMIC ACID; PARTICLE SIZE; SOLUBILITY; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84872369196     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.12.001     Document Type: Article

References (34)

1. The Merck Index 2012, Merck & Co. Inc., Rahway, NJ, (http://themerckindex.chemfinder.com). 14th ed.
2. Martindale, The Extra Pharmacopoeia 2011, The Royal Pharm. Society, London, pp 234-282. 37th ed.
3. Ambrus R., Aigner Z., Dehelean C., Soica C., Szabó-Révész P. Physico-chemical studies on solid dispersions of niflumic acid prepared with PVP. Rev. Chim. 2007, 58:60-64.
4. Ambrus R., Aigner Z., Soica C., Peev C., Szabó-Révész P. Amorphisation of niflumic acid with polyvinylpyrrolidone prepared solid dispersion to reach rapid drug release. Rev. Chim. 2007, 58:206-209.
5. Kata M., Ambrus R., Aigner Z. Preparation and investigation of inclusion complexes containing niflumic acid and cyclodextrins. J. Inc. Phenom. 2002, 44:123-126.
6. Szunyogh T., Ambrus R., Szabó-Révész P. Importance of particle size decrease in the preformulation. Acta Pharm. Hung. 2011, 81:29-36.
7. Kanzer J., Hupfeld S., Vasskog T., Tho I., Hölig P., Mägerlein M., Fricker G., Brandl M. In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation. J. Pharm. Biomed. Anal. 2010, 53:359-365.
8. Zhang J., Lv H., Jiang K., Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int. J. Pharm. 2011, 420:180-188.
9. Prow T.W., Grice J.E., Lin L.L., Faye R., Butler M., Becker W., Wurm E.M.T., Yoong C., Robertson T.A., Soyer H.P., Roberts M.S. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev. 2011, 63:470-491.
10. Chen H., Kou X., Yang Z., Ni W., Wang J. Shape- and size-dependent refractive index sensitivity of gold nanoparticles. Langmuir 2008, 24:5233-5237.
11. Missirlis D., Tirelli N., Hubbel J.A. Amphiphilic hydrogel nanoparticles preparation characterization and preliminary assessment as new colloidal drug carriers. Langmuir 2005, 21:2605-2613.
12. Kim J.-W., Shin M.-S., Kim J.-K., Kim H.-S., Koo K.-K. Evaporation crystallization of RDX by ultrasonic spray. Ind. Eng. Chem. Res. 2011, 50:12186-12193.
13. Ambrus R., Kocbek P., Kristl J., Sibanc R., Rajkó R., Szabó-Révész P. Investigation of preparation parameters to improve the dissolution rate of poorly soluble meloxicam. Int. J. Pharm. 2009, 318(2):153-159.
14. Saharan V.A., Kukkar V., Kataria M., Gera M., Choudhury P.M. Dissolution enhancement of drugs. Part I: technologies and effect of carriers. Int. J. Health Res. 2009, 2:107-124.
15. Liversidge G.G., Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995, 125:309-313.
16. Liu P., Rong X., Laru J., von Veen B., Kiesvaara J., Hiruonen J., Laaksonen T., Peltonen L. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int. J. Pharm. 2011, 411:215-222.
17. Müller R.H., Akkar A. Drug nanocrystals of poorly soluble drugs. Encyclop. Nanosci. Nanotechnol. 2004, 2:627-638.
18. Kocbek P., Baumgartner S., Kristl J. Preparation and evaluation of nanosuspension for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 2006, 312:179-186.
19. Yasuji T., Takeuchi H., Kawashima Y. Particle design of poorly water-soluble substances using supercritical fluid technologies. Adv. Drug. Dev. Rev. 2008, 60:388-398.
20. Radacsi N., Stankiewicz A.I., Creyghton Y.L.M., van der Heijden A.E.D.M., ter Horst J.H. Electrospray crystallization for high-quality submicron-sized crystals. Chem. Eng. Technol. 2011, 34:624-630.
21. Yurteri C.U., Hartman R.P.A., Marijnissen J.C.M. Producing pharmaceutical particles via electrospraying with an emphasis on nano and nano structure particles - a review. KONA Powder Particle J. 2010, 28:91-115.
22. Jaworek A. Micro- and nanoparticle production by electrospraying. Powder Technol. 2007, 176:18-35.
23. Almería B., Deng W., Fahmy T.M., Gomez A. Controlling the morphology of electrospray-generated PLGA microparticles for drug delivery. J. Colloid Interf. Sci. 2010, 343:125-133.
24. Rayleigh L. Comparison of methods for the determination of resistances in absolute measure. Phil. Mag. 1882, 14:184-186.
25. Revalor E., Hammadi Z., Astier J.P., Grossier R., Garcia E., Hoff C., Furuta K., Okutsu T., Morin R., Veesler S. Usual and unusual crystallization from solution. J. Cryst. Growth 2010, 312:939-946.
26. Radacsi N., Ambrus R., Szunyogh T., Szabó-Révész P., Stankiewicz A.I., van der Heijden A.E.D.M., ter Horst J.H. Electrospray crystallization for nano-sized pharmaceuticals with improved properties. Cryst. Growth Des. 2012, 12:3514-3520.
27. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with image. J. Biophoton. Int. 2004, 11:36-42.
28. Wagner M. Thermal analysis in practice. DSC evaluations 2009, Mettler Toledo, Schwerzenbach, pp. 90-141.
29. Arias-Blanco M.J., Moyano J.R., Perez-Martinez J.I., Gines J.M. Study of the inclusion of gliclazide in α-cyclodextrin. J. Pharm. Biomed. Anal. 1998, 18:275-279.
30. H.A. Crisp, J.C. Clayton, L.G. Elliott, E.M. Wilson, Preparation of a highly pure substantially amorphous form of cefuroxime axetil, U.S. Patent 4,820,1833, (1989).
31. Nakayamaa S., Watanabec T., Sennaa M. Rapid amorphization of molecular crystals by absorption of solvent molecules in the presence of hydrophilic matrices. J. Alloy. Compd. 2009, 483:217-221.
32. Yang G.C., Nie F.D., Li J.S. Preparation and characterization of nano-NTO explosive. J. Energ. Mater. 2007, 25:35-47.
33. Takács-Novák K., Avdeef A., Box K.J., Podányi B., Gy Szász Determination of protonation macro- and microconstants and octanol/water partition coefficient of antiinflammatory drug niflumic acid. J. Pharm. Biomed. Anal. 1994, 12:1369-1377.
34. Murthy H.M.K., Vijayan M. 2[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid (niflumic acid). Acta Crystallogr. 1979, 35:262-263.